Results 51 to 60 of about 4,565 (192)

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients

Cancer Medicine, 2021
Background There was no standard treatment for patients who acquired resistance to osimertinib mediated by epidermal growth factor receptor (EGFR) T790M‐cis‐C797S.
Yaning Yang, Haiyan Xu, Li Ma, Lu Yang, Guangjian Yang, Shuyang Zhang, Xin Ai, Shucai Zhang, Yan Wang   +8 more
doaj   +1 more source

Linguistic measures of chemical diversity and the "keywords" of molecular collections [PDF]

, 2018
Computerized linguistic analyses have proven of immense value in comparing and searching through large text collections ("corpora"), including those deposited on the Internet-indeed, it would nowadays be hard to imagine browsing the Web without,
A Cadeddu, A Kilgarriff, A Roy, B Kowalczyk, B Zhang, C Bian, C Lipinski, D Conte, D Hoover, EJ Martin, F Font-Clos, F Tweedie, FW Goldberg, G Skoraczyński, GM Maggiora, GM Rishton, JW Raymond, K Kettunen, M Krallinger, M Kubát, M Suggitt, MA Covington, ME Welsch, MM Cone, NG Olinghouse, S Soh, WP Walters, Y Cao   +27 more
core   +2 more sources

Presentation and Outcomes of CNS Tumors Associated With Phakomatoses Syndromes From a Specialized Neuro‐Oncology Practice in India

Cancer Medicine, Volume 15, Issue 2, February 2026.
Encouraging survival is achieved in phakomatosis syndromes with conventional multimodality treatment (Surgery, RT, chemotherapy). There is an urgent need for easily administered systemic therapies which improve both quality and quantity of life. ABSTRACT Purpose Phakomatoses‐associated primary central nervous system (CNS) tumors are therapeutically ...
Anuradha Krishnan, Yamini Baviskar, Abhishek Chatterjee, Archya Dasgupta, Sridhar Epari, Arpita Sahu, Girish Chinnaswamy, Nandini Menon, Aliasgar Moiyadi, Tejpal Gupta, Jayant Sastri‐Goda   +10 more
wiley   +1 more source

ALK, ROS1 and EGFR next-generation tyrosine kinase inhibitors in advanced non-small-cell lung cancer [PDF]

, 2019
Non-small-cell lung cancer (NSCLC) is the most common cancer in men and the second most common in fe- males. In previous years the significance of some molecular disorders in pathogenesis NSCLC was proven and the value of targeted therapies in the ...
Krzakowski, Maciej, Piórek, Aleksandra, Winiarczyk, Kinga   +2 more
core   +2 more sources

Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients [PDF]

, 2022
Brigatinib was recently approved for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer and is dosed according to a one-dose-fits-all paradigm.
Koele, Simon E., Piet, Berber, ter Heine, Rob, van Beek, Stijn W., van den Heuvel, Michel M., van der Wekken, Anthonie J.   +5 more
core   +2 more sources

A Giant Thoracic ALK‐Rearranged Mesenchymal Neoplasm in a Child

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Mesenchymal neoplasms characterized by ALK fusions mainly include inflammatory myofibroblastic tumors (IMTs) and epithelioid fibrous histiocytomas (EFHs). More recently, ALK‐rearranged mesenchymal tumors that are not IMTs or EFHs, characterized by S100 and CD34 coexpression, have been reported in a few small series and isolated case
Sheng Gao, Junhua Wu, Jun Fan, Xiaona Chang, Bo Huang, Danju Luo, Jun He, Heshui Shi, Xiaochuan Dong, Xiu Nie   +9 more
wiley   +1 more source

Treatment Sequencing Strategies in Lung Cancer

Chinese Journal of Lung Cancer, 2022
Background and objective The advances in the lung cancer screening methods and therapeutics, together with awareness towards deleterious habits, such as smoking, is increasing the overall survival with better quality of life for the patients.
Daniel Humberto Pozza, Ramon Bezerra Andrade de Mello   +1 more
doaj   +1 more source

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer

npj Precision Oncology
Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge.
Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama   +15 more
doaj   +1 more source

Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangement

Frontiers in Oncology
PurposeThe use of neoadjuvant anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has not been extensively explored. The current case report highlights the notable pathological complete response (pCR) achieved following neoadjuvant ...
Hayoung Seong, Hayoung Seong, Soo Han Kim, Soo Han Kim, Mi Hyun Kim, Mi Hyun Kim, Jeong Su Cho, Ahrong Kim, Jung Seop Eom, Jung Seop Eom, Jung Seop Eom   +10 more
doaj   +1 more source